Check Point ON TRACK With Q2 Estimates and 4 Stock Analyses to Know Now
Wright Medical Group Inc. (NASDAQ:WMGI): Jefferies thinks Stryker’s (NYSE:SYK) report that it is recalling its Rejuvenate and ABG II modular hip systems will probably bring back worries over Wright Medical’s PROFEMUR. The firm thinks the effect on Wright medical may be notable and reiterates a Hold rating on the stock.
Check Point Software Technologies Ltd. (NASDAQ:CHKP): After conducting checks, Oppenheimer thinks Check Point is situated to turn in around in-line Q2 results. The firm believes good catalysts for the company in Europe will offset moderating spending in that region, and it reiterates an Outperform rating on the stock.
Don’t Miss: Oracle Is Turning Up The Social Media HEAT.
Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR): SunTrust believes there is fair value of Questcor in the $38-41 range as opposed to its present price of $57.64. the firm does not think there is a pathway for an AB-rated generic of Acthar but reported that Novartis could employ the patient safety experience from Europe and make a competing product that can be approved in 2014. The firm thinks Questcor will have a notable rise in R&D but will require the clinical data to make in-roads in bigger markets. Shares are rated Neutral.
Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR): Oppenheimer thinks Questcor’s stock fell 22% because of worries, started by an investor blog, regarding the advent of pharmaceuticals that will compete with the company’s Acthar. Oppenheimer believes such competition will not materialize for years, and holds to a $59 target and Outperform rating on the stock.
Bridgepoint Education, Inc. (NYSE:BPI): Following the denial of accreditation for Bridgepoint’s Ashford by the Western Association of Schools and Colleges, Wells Fargo believes Ashford can preserve accreditation if it responds eagerly to its accreditor’s concerns. Wells Fargo believes these concerns can be addressed readily, but will necessitate more spending by the company. The firm reiterates a $28-31 valuation range and a rating of Outperform on the stock.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.